Tumor microenvironment colonization by Escherichia coli Nissle 1917 (EcN tumor colonization)

The tumor microenvironment colonization by *Escherichia coli* Nissle 1917 (EcN) refers to the ability of this well-characterized probiotic bacterial strain to preferentially home to and proliferate within solid tumors after systemic or oral administration. This property leverages unique features of the tumor microenvironment, such as hypoxia, necrosis, and immune evasion, to enable highly selective colonization not observed in most healthy tissues. While EcN itself is not considered a traditional molecular therapeutic target (such as proteins, enzymes, or receptors), it functions as a living, engineerable chassis for drug delivery, immune modulation, and tumor detection. Engineered EcN has shown efficacy in preclinical models for reducing tumor burden and delivering imaging agents. Its clinical safety record in gastrointestinal disorders is robust, but concerns remain regarding the production of genotoxins like colibactin, particularly for cancer patients. Colonization by EcN is being actively explored in oncology as both a therapeutic and a diagnostic tool, but a detailed mechanistic understanding of its tumor tropism is still developing

Other names

Colonization of tumor microenvironment by Escherichia coli Nissle 1917Tumor tropism of EcNTumor-homing E. coli Nissle 1917Tumor-targeting EcN

Selective colonization of tumor tissue, especially hypoxic/necrotic regions Serves as a vector for delivering therapeutic payloads (e.g., proteins, immunomodulators) to the tumor microenvironment Elicits local immune responses, especially Th1-type responses in tumors Enables tumor detection via engineered production of reporter molecules